Israel's NeuroDerm (the page is currently a placeholder), a biotech developing drug patches for neurological disorders such as Parkinson's disease, raised $2.5 million in a first round of funding. The investment was provided by private individuals, including Robert Taub, founder and CEO of Omrix Pharmaceuticals.
NeuroDerm, based in Ofakim, Israel, is at work on a skin patch that will allow continuous delivery of levadopa, a drug now used to treat Parkinson's. Continuous delivery of the drug may help many patients avoid motor complications, the company says.